Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 190
- Registration Number
- NCT02110394
- Locations
- 🇷🇺
RONC n.a.N.N.Blokhin/21, Moscow, Russian Federation
🇷🇺Alexandro-Mariinskaia Regional Clinical Hospital/13, Astrakhan', Russian Federation
🇷🇺Vologda Reginal Clinical Hospital #2, Cherepovets, Russian Federation
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 89
- Registration Number
- NCT02108548
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 6
- Registration Number
- NCT02106780
- Locations
- 🇬🇧
Covance CRU Ltd., Leeds, United Kingdom
A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 2000
- Registration Number
- NCT02087098
- Locations
- 🇨🇿
Site CZ42001 Private Practice, Beroun, Czech Republic
🇨🇿Site CZ42003 Private Practice, Benešov, Czech Republic
🇨🇿Site CZ42014 Private Practice, Blansko, Czech Republic
A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 25
- Registration Number
- NCT02083627
- Locations
- 🇩🇪
Parexel GmbH, Berlin, Germany
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 97
- Registration Number
- NCT02072967
- Locations
- 🇷🇺
City Clinical Hospital #8, Barnaul, Russian Federation
🇷🇺Chelyabinsk Regional Oncology Dispensary/15, Chelyabinsk, Russian Federation
🇷🇺Vologda Regional Clinical Hospital #2, Cherepovets, Russian Federation
A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 132
- Registration Number
- NCT02065349
- Locations
- 🇨🇿
Site: CZ42003, Chocen, Czechia
🇨🇿Site: CZ42004, Litomysl, Czechia
🇨🇿Site: CZ42001, Rychnov nad Kneznou, Czechia
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 6
- Registration Number
- NCT02046798
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1829
- Registration Number
- NCT02045862
- Locations
- 🇺🇸
Site US10133, Los Angeles, California, United States
🇺🇸Site US10553, Lincoln, Nebraska, United States
🇺🇸Site US10148, Hialeah, Florida, United States
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT02034734
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom